Related Experiment Video
Updated: Jun 9, 2026

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
Ethical Considerations in Carbamazepine Pharmacogenomics Testing
Madeline Yuzwa1, Rachel Conrad Bracken2
1Department of Pharmacy, Northeast Ohio Medical University.
Abstract:
Carbamazepine, a widely used anticonvulsant, exemplifies both the promise and challenges of pharmacogenomics in personalized medicine. This paper critically examines the ethical implications of pharmacogenomic testing for carbamazepine, focusing on the limitations of current FDA guidelines. Through a comprehensive literature review and ethical analysis, we argue that these guidelines inadequately address key ethical concerns, including patient privacy, autonomy, equitable access, and potential genetic discrimination. We propose an updated framework for ethical implementation of pharmacogenomic testing, emphasizing four key areas: ensuring consistent and equitable access to testing, comprehensive patient education and informed consent, robust patient privacy and data management practices, and culturally aware approaches to genetic counseling. Our recommendations call for interdisciplinary collaboration to develop more comprehensive guidelines that balance clinical efficacy with ethical considerations in the rapidly evolving field of pharmacogenomics.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenomics: Identification of New Drug Targets
Principles of Pharmacogenetics: Types of Genetic Variants
